Cargando…
Trial Watch: Proteasomal inhibitors for anticancer therapy
The so-called “ubiquitin-proteasome system” (UPS) is a multicomponent molecular apparatus that catalyzes the covalent attachment of several copies of the small protein ubiquitin to other proteins that are generally (but not always) destined to proteasomal degradation. This enzymatic cascade is cruci...
Autores principales: | Obrist, Florine, Manic, Gwenola, Kroemer, Guido, Vitale, Ilio, Galluzzi, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904962/ https://www.ncbi.nlm.nih.gov/pubmed/27308423 http://dx.doi.org/10.4161/23723556.2014.974463 |
Ejemplares similares
-
Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
por: Manic, Gwenola, et al.
Publicado: (2015) -
Chloroquine and hydroxychloroquine for cancer therapy
por: Manic, Gwenola, et al.
Publicado: (2014) -
Trial Watch: Anticancer radioimmunotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013) -
Trial Watch: Adoptive cell transfer for anticancer immunotherapy
por: Aranda, Fernando, et al.
Publicado: (2014) -
Trial Watch: DNA vaccines for cancer therapy
por: Pol, Jonathan, et al.
Publicado: (2014)